Multiple Myeloma Clinical Trial

Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma

Summary

Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate PET CT, and C-11 acetate PET MRI) is the best test for finding sites of active myeloma disease.

View Full Description

Full Description

Participants who are clinically scheduled to undergo F-18 FDG PET/CT myeloma evaluation will also undergo F-18 FDG PET/MRI, and C-11 acetate PET CT/MRI. On Day 1 of study, participants will undergo F-18 FDG PET/CT-MRI. F-18 FDG radiopharmaceutical is infused intravenously, followed by a 60 minute waiting uptake phase. After 60 minutes, participant will undergo PET/CT imaging for 30 minutes. At 90 minutes, participant will undergo PET/MRI imaging for 30 minutes. On Day 2 of study, participants will undergo C-11 PET/CT-MRI. C-11 radiopharmaceutical is infused intravenously, followed by a 10 minute uptake phase. After 10 minutes, participant will undergo PET/CT imaging for 30 minutes, followed by a 60 minute pause with the participant at rest. At the end of 60 minute pause, the participant is given the second C-11 acetate infusion, followed by a 10 minute waiting uptake phase. After 10 minutes, participant will undergo PET/MRI imaging for 30 minutes. On Day 3, study team member makes a phone call to participant for follow up.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients being staged for multiple myeloma as follows: new diagnosis, high risk smoldering multiple myeloma, relapsed as defined by investigator
Patients who have undergone standard of care workup
300 pounds or less
Can provide informed consent
Scheduled for a clinically indicated F-18 FDG PET scan
English speaking

Exclusion Criteria:

Pregnant, breast feeding
Concurrent active non-multiple myeloma malignancy
Contraindication to PET MRI
Previous Type I or Type II Diabetes mellitus or a fasting blood glucose >150 mg/dl

Study is for people with:

Multiple Myeloma

Phase:

Phase 2

Estimated Enrollment:

10

Study ID:

NCT03262389

Recruitment Status:

Completed

Sponsor:

Michael C Roarke, MD

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Mayo Clinic in Arizona
Scottsdale Arizona, 85259, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 2

Estimated Enrollment:

10

Study ID:

NCT03262389

Recruitment Status:

Completed

Sponsor:


Michael C Roarke, MD

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider